Eiger BioPharmaceuticals, Inc. Stock News

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will part

BidaskClub cut shares of Eiger Biopharmaceuticals (NASDAQ:EIGR) from a sell rating to a strong sell rating in a research report released on Friday morning, BidAskClub reports. Other research analysts

I have been discussing the idea that the tragic coronavirus pandemic presents a unique opportunity in which a healthcare event can lead to profitable investments.

Every investor in Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) should be aware of the most powerful shareholder...

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile market

Eiger BioPharma (EIGR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Deutsche Bank AG increased its stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 306.4% in the 1st quarter, HoldingsChannel reports. The firm owned 52,683 shares of the biotechnology co

Nuveen Asset Management LLC boosted its holdings in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 196.9% during the 1st quarter, according to the company in its most recent disclosure with the Securit

Two Sigma Advisers LP grew its stake in Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 216.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange C

After Canaccord Genuity and Needham gave Rhythm Pharmaceuticals (NASDAQ: RYTM) a Buy rating last month, the company received another Buy,

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS –

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Achieve Life Sciences (ACHV –

Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Two Sigma Investments LP grew its holdings in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) by 112.6% in the first quarter, according to its most recent filing with the Securities and Exchange